Compare DSX & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DSX | SGMT |
|---|---|---|
| Founded | 1999 | 2006 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.0M | 204.2M |
| IPO Year | 2005 | 2023 |
| Metric | DSX | SGMT |
|---|---|---|
| Price | $2.42 | $5.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $27.00 |
| AVG Volume (30 Days) | 650.4K | ★ 800.4K |
| Earning Date | 02-26-2026 | 03-11-2026 |
| Dividend Yield | ★ 1.71% | N/A |
| EPS Growth | ★ 231.99 | N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $218,560,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.40 | $125.00 |
| P/E Ratio | $15.55 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.27 | $1.73 |
| 52 Week High | $2.39 | $11.41 |
| Indicator | DSX | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 69.07 | 39.15 |
| Support Level | $2.17 | $5.31 |
| Resistance Level | $2.33 | $5.74 |
| Average True Range (ATR) | 0.10 | 0.52 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 95.32 | 8.70 |
Diana Shipping Inc provides shipping transportation services. The company, through its subsidiaries, operates a fleet of vessels consisting of dry bulk carriers such as Panamax, Kamsarmax, Post-Panamax, Capesize and Newcastlemax vessels. Using this fleet, the firm provides transportation services for various goods including coal, iron ore, and grains. It also transports minor bulks, including steel products, cement, and fertilizers through its dry bulk carrier vessels. The operation of the vessels is the main source of revenue generation, the services provided by the vessels are similar and all operate under the same economic environment.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.